2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
3
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
9481
Neoplasms
6589
Prostatic Neoplasms
4399
Colorectal Neoplasms
3978
Lung Neoplasms
3644
Carcinoma, Non-Small-Cell Lung
3585
Pancreatic Neoplasms
2479
Carcinoma, Hepatocellular
2413
Leukemia, Myeloid, Acute
2265
Multiple Myeloma
2121
Stomach Neoplasms
2109
Neoplasm Metastasis
1911
Head and Neck Neoplasms
1870
Ovarian Neoplasms
1773
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1734
Lymphoma
1730
Brain Neoplasms
1702
Rectal Neoplasms
1676
Melanoma
1656
Colonic Neoplasms
1629
Leukemia
1500
Uterine Cervical Neoplasms
1499
Recurrence
1486
Esophageal Neoplasms
1312
Glioblastoma
1308
Lymphoma, Non-Hodgkin
1205
Leukemia, Lymphocytic, Chronic, B-Cell
1120
Squamous Cell Carcinoma of Head and Neck
1109
Urinary Bladder Neoplasms
1078
Lymphoma, Follicular
1067
Interventions
Pluvicto
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
×
Clear all
NCT06943495
2025-09-09
PRODIGY-2
CHU de Quebec-Universite Laval
Phase 1
Recruiting
60 enrolled